ThermoGenesis Holdings (NASDAQ:THMO) changed 18.33% to recent value of $4.26. The stock transacted 826935 shares during most recent day however it has an average volume of 333.14K shares. It spotted trading -45.38% off 52-week high price. On the other end, the stock has been noted 161.35% away from the low price over the last 52-weeks.
On April 13, 2020, ThermoGenesis Holdings (NASDAQ:THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, disclosed that its joint venture, ImmuneCyte Life Sciences, has completed the acquisition of worldwide intellectual property for developing fully human antibody therapeutics for COVID-19. The acquired intellectual property includes four high-affinity monoclonal antibody drug candidates against SARS-CoV-2 (the virus causing COVID-19) and tools for screening and quantifying efficacy of such neutralizing antibodies. These high-affinity neutralizing monoclonal antibodies were obtained from the screening of enriched B cell libraries from individuals who have recently recovered from COVID-19 (i.e. from convalescent whole blood). The technologies were originally developed by a research team affiliated with East China Normal University, one of the most prestigious universities in China. The acquisition includes an undisclosed upfront cash payment and low double-digit future revenue sharing for the monoclonal antibody drug candidates under development. ThermoGenesis currently holds approximately 19% of the equity of ImmuneCyte.
There are currently no regulatory approved vaccine or drug therapies for COVID-19. Current estimates are that a vaccine for emergency use may be available by early 2021. Convalescent plasma therapy is an exploratory approach that involves giving patients an infusion of plasma from people who have recovered from COVID-19. ThermoGenesis is developing a convalescent plasma strategy for COVID-19 with its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit, which, together with ImmuneCyte’s newly acquired technologies, can quickly identify individuals who have developed protective immunity against the virus, and then, using ThermoGenesis’ proprietary cell processing platform, allows for the simultaneous isolation of convalescent plasma and immune cells for potential anti-COVID-19 antibody development.
THMO has a gross margin of 43.60% and an operating margin of -42.30% while its profit margin remained -72.80% for the last 12 months. Its earnings per share (EPS) expected to touch remained 84.40% for this year.
The company has 4.42M of outstanding shares and 3.86M shares were floated in the market. According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 39.12% from the mean of 20 days, 9.86% from mean of 50 days SMA and performed 6.97% from mean of 200 days price. Company’s performance for the week was 11.81%, 54.29% for month and YTD performance remained -3.18%.